RussellS, BennettJ, WellmanJA, et al.Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, Phase 3 trial. Lancet, 2017; 390:849–860.
2.
GaudetD, MéthotJ, DéryS, et al.Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther, 2013; 20:361–369.
3.
SchimmerJ, BreazzanoS. Investor outlook: rising from the ashes; GSK's European approval of Strimvelis for ADA-SCID. Hum Gene Ther Clin Dev, 2016; 27:57–61.
4.
MaudeSL, LaetschTW, BuechnerJ, et al.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 2018; 378:439–448.
5.
NeelapuSS, LockeFL, BartlettNL, et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med, 2017; 377:2531–2544.
6.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
7.
SontheimerEJ, BarrangouR. The bacterial origins of the CRISPR genome-editing revolution. Hum Gene Ther, 2015; 26:413–424.
8.
FlotteTR. Ethical implications of the cost of molecularly targeted therapies. Hum Gene Ther, 2015; 26:573–574.
9.
SilvermanE. Kymriah: a sign of more difficult decisions to come. Manag Care, 2018; 27:17.
10.
NASDAQ Composite—45 year historical chart. https://www.macrotrends.net/1320/nasdaq-historical-chart (last accessed November24, 2018).
11.
National Institutes of Health. FY 2019 Ruth L. Kirschstein National Research Service Award (NRSA) stipends, tuition/fees, and other budgetary levels. https://nexus.od.nih.gov/all/ (last accessed November24, 2018).
12.
FuhrmannCN. Enhancing graduate and postdoctoral education to create a sustainable biomedical workforce. Hum Gene Ther, 2016; 27:871–879.
